

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

02 FEB 14 PM 3:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pharmaceutical Research & Manufacturers of America			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1100 15th Street, N.W., Suite 900 City Washington State/Zip (or Country) DC 20005 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Matthew B. Van Hook	Telephone 202.835.3513	E-mail (optional) mvanhook@phrma.org	5. Senate ID # 31350-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 30654000

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$5,500,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate reporting accounting method. See instructions for description of method. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions <input type="checkbox"/> Method B. Reporting amounts under section 6033(c) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature _____ Date 2/14/02



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H.R. 2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations 2002; , FDA Appropriations

H.R. 3061, Labor-HHS Appropriations, 2002; , NIH Return-On-Investment Amendment

S. 1191, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations 2002; , FDA Appropriations and Amendments Re Reimportation

17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bantham, Russel	
Currie, Rodger	
Deschenes, Elise	Legislative Assistant, Rep. George Nethercutt, Jr.
Guarducci, Mara.	
Holmer, Alan F.	
Jenkins, Missy	
Mohler, Dave T.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/02

Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
18a	Lobbyist Name	Olsen, Scott
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Pomfret, Jacqui
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Stewart, Shelley
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Van Hook, Matthew B.
18b	Covered Official Position	
18c	New Lobbyist	No



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

**H.R. 1708, Affordable Prescription Drugs and Medical Inventions Act ,
S. 754, Drug Competition Act of 2001,
S. 812 and H.R. 1862, Greater Access To Affordable Pharmaceuticals Act,**

17. House(s) of Congress and Federal agencies contacted

Check if None

**House of Representatives
Patent and Trademark Office
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bantham, Russel	
Currie, Rodger	
Guarducci, Mara	Legislative Assistant, Rep. Jim Greenwood
Holmer, Alan F.	
Mohler, Dave T.	
Olsen, Scott	
Pomfret, Jacqui	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____

Date 2/14/02



Registrant Name: **Pharmaceutical Research & Manufacturers of America**

Client Name: **Self**

Item	Description	Data
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Van Hook, Matthew B.
18b	Covered Official Position	
18c	New Lobbyist	No



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- H.R. 1387, Drug Availability and Health Care Access Improvement Act of 2001,
- H.R. 1400, Prescription Drug Fairness for Seniors Act of 2001, price controls on drugs for Medicare benefici
- H.R. 1644, Human Cloning Prohibition Act of 2001,
- H.R. 1717, To require to require Department of Veterans Affairs pharmacies to dispense medications to veter
- prescriptions written by private practitioners,
- H.R. 2887, Best Pharmaceuticals for Children Act,
- H.R. 3448, Public Health Security and Bioterrorism Response Act of 2001,
- H.R. 58, Medicine Equity and Drug Safety Act Corrections of 2000, restrain FDA regulation of drug imports
- H.R. 68, To amend the Food, Drug, and Cosmetic Act relating to the distribution chain of prescription drugs
- of Prescription Drug Marketing Act. limitations re pedigree requirements for unauthorized distributors
- S. 1229, Personal Prescription Drug Import Fairness Act,

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bantham, Russel	
Currie, Rodger	
Deschenes, Elise	Legislative Assistant, Rep. George Nethercutt, Jr.
Guarducci, Mara.	
Holmer, Alan F.	
Jenkins, Missy	
Lucas, William	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/02



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S. 1032, International Infectious Diseases Control Act of 2001, expansion of assistance to countries seriously affected by HIV/AIDS, Malaria and Tubercu
16	Lobbying Issues	S. 1120, Global AIDS Research and Relief Act of 2001, expansion of FY02 appropriations and authorization of FY03 appropriations to combat HIV/AID
16	Lobbying Issues	S. 1132, To amend the Food, Drug, and Cosmetic Act relating to the distributi chain of prescription drugs, relaxation of Prescription Drug Marketing Act.
16	Lobbying Issues	S. 1765, Bioterrorism Preparedness Act of 2001,
16	Lobbying Issues	S. 1789, Best Pharmaceuticals for Children Act,
16	Lobbying Issues	S. 215, Medication Equity and Drug Savings Act,
16	Lobbying Issues	S. 699, Prescription Drug Fairness for Seniors Act of 2001, price controls on d for Medicare beneficiaries.
16	Lobbying Issues	S. 812 and H.R. 1862, Greater Access To Affordable Pharmaceuticals Act,
16	Lobbying Issues	S. 838, Best Pharmaceuticals for Children Act,
16	Lobbying Issues	Reauthorization of the Prescription Drug User Fee Act
16	Lobbying Issues	Executive Branch: FDA implementation of P.L. 105-115, the FDA Modernization Act of 1997; Reauthorization of the Prescription Drug User Fee Act
18a	Lobbyist Name	Mohler, Dave T.
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Olsen, Scott
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Pomfret, Jacqui
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Reilly, Lori
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Stewart, Shelley
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Van Hook, Matthew B.
18b	Covered Official Position	
18c	New Lobbyist	No



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)
16. Specific Lobbying issues
S. 1177, Access to Affordable Prescription Drugs Act of 2001,
S. 1239, Medicare Rx Drug Discount and Security Act of 2001, to provide Medicare beneficiaries with a drug card.
S. 357, Medicare Preservation and Improvement Act of 2001 (Breux-Frist I),
S. 358, Medicare Prescription Drug and Modernization Act of 2001 (Breux-Frist II),
S. 925, Medicare Extension of Drugs to Seniors (MEDS) Act of 2001,
Executive Branch:
Medicare reimbursement issues.

17. House(s) of Congress and Federal agencies contacted Check if None
Health Care Financing Administration, Dept. of Health and Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Currie, Rodger	
Guarducci, Mara.	
Holmer, Alan F.	
Jenkins, Missy	
Lucas, William	
Mohler, Dave T.	
Olsen, Scott	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/02



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Item	Description	Data
18a	Lobbyist Name	Pomfret, Jacqui
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Reilly, Lori
18b	Covered Official Position	
18c	New Lobbyist	No
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No
18a	Lobbyist Name	Stewart, Shelley
18b	Covered Official Position	
18c	New Lobbyist	No



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R. 1836, Economic Growth and Tax Relief Reconciliation Act of 2001, Amendment to permanently extend & development tax credit.

H.R. 41 and S. 41, A bill to To amend the Internal Revenue Code of 1986 to permanently extend the research to increase the rates of the alternative incremental credit. ,

Department of the Treasury development of a Foreign Sales Corporation replacement proposal in response t of the World Trade Organization.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Currie, Rodger	
Guarducci, Mara.	
Holmer, Alan F.	
Rubin, Peter	Legislative Director for Rep. Jim McDermott
Van Hook, Matthew B.	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/14/02



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

**H.R. 1185, Global Access to HIV/AIDS Medicines Act of 2001,
H.R. 2069, Global Access to HIV/AIDS Prevention, Awareness, Education, and Treatment Act of 2001,
H.R. 2603, United States-Jordan Free Trade Area Implementation Act,
H.R. 933, Affordable HIV/AIDS Medicines for Poor Countries Act,
Executive Branch:
Strengthening protection of Intellectual property abroad.**

17. House(s) of Congress and Federal agencies contacted

Check if None

**Department of Commerce
House of Representatives
Office of the United States Trade Representative
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Currie, Rodger.	
Herzfeld, Shannon S.S.	
Holmer, Alan F.	
Lucas, William	
Mohler, Dave T.	
Olsen, Scott	
Pomfret, Jacqui	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date 2/14/02



Registrant Name: **Pharmaceutical Research & Manufacturers of America**

Client Name: **Self**

Item	Description	Data
18a	Lobbyist Name	Rubin, Peter
18b	Covered Official Position	Legislative Director for Rep. Jim McDermott
18c	New Lobbyist	No



Registrant Name: Pharmaceutical Research & Manufacturers of America

Client Name: Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Walters, William

Gradler, Rebecca

Lynch, Ann-Marie

Bello, Judith

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Bus (city and state or cour


26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrar or affiliated organization

Signature 

Date 2/14/02

